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Patients were randomised (1:1) to celecoxib 200 mg twice daily or placebo for two years. 45 Patients with intermediate risk NMIBC were recommended to receive 6 weekly mitomycin 46 C; high risk NMIBC cases received 6 weekly Bacillus Calmette Guérin and maintenance 47 therapy. 48 Outcome measurements and statistical analysis 49 The primary endpoint was time to disease recurrence. Analysis was by intention to treat. 50 Results and limitations 51 BOXIT primary analysis manuscript submitted to European Urology -reviewed 3 A total of 472 patients were randomised (236:236) . With median follow-up of 44 months 52 (IQR: 36-57), 3-year recurrence-free rate (RFR) (95% CI) was celecoxib: 68% (61%-74%) 53 versus placebo: 64% (57%-70%) (hazard ratio (HR) 0.82, [0.60-1.12], p=0.2). There was no 54 difference in high ], p=0.2) or intermediate risk ], 55 p=0.7) NMIBC. Subgroup analysis suggested time to recurrence was longer in pT1 NMIBC 56 patients treated with celecoxib compared to placebo (HR: 0.53, , interaction test 57 p=0.04). The 3-year progression rates in high risk patients were low: 10% (6.5%-17%) and 58 9.7% (6.0%-15%) in celecoxib and placebo arms respectively. Incidence of serious 59 cardiovascular events was higher in celecoxib (5.2%) than placebo (1.7%) (difference +3.4% 60 [-0.3%-7 .2%], p=0.07).
61
Conclusion 62 BOXIT did not show that celecoxib reduces the risk of recurrence in intermediate or high risk 63 NMIBC although celecoxib was associated with delayed time to recurrence in pT1 NMIBC 64 patients. The increased risk of cardiovascular events does not support the use of celecoxib.
Introduction

73
Bladder cancer represents the 9 th most common cancer with 429,000 new cases per year 74 worldwide [1] . Over 75% of new cases are non-muscle invasive bladder cancer (NMIBC) and 75 following tumour resection, between 28-52% of patients will develop recurrence within 5 76 years [2] . Efforts to reduce recurrence of NMIBC include the use of intravesical 77 chemotherapy and Bacillus Calmette Guérin (BCG) [3, 4] . 78 Cyclo-oxygenase (COX) enzyme controls a rate limiting step implicated in carcinogenesis by 79 regulating the conversion of arachidonic acid to prostaglandin E2 (PGE2) and inhibits 80 apoptosis by overexpressing Bcl-2 [5]. Inhibition of COX-2 results in cell cycle arrest 81 triggering apoptosis in in vitro studies [6] . A population-based case-controlled study 82 reported that patients taking regular NSAIDs had an a lower risk of developing bladder 83 cancer (odds ratio 0.81, 95% CI: 0.68-0.96) compared to non-or irregular NSAID use patients 84 [7] . Consistent with this, COX-2 is overexpressed in bladder cancer compared to normal 85 urothelium and COX-2 expression is associated with disease recurrence and progression [8] . 86 A phase II randomised controlled trial (RCT) comparing celecoxib, a selective COX-2 87 inhibitor, to placebo in high risk NMIBC recruited subjects who received adjuvant BCG was 88 reported by Sabichi and colleagues [9] . It was powered to detect a large treatment effect of 89 53% relative reduction in recurrence at 12 months but failed to show a difference [9] . 90 Further, the study did not assess health related quality of life (HRQOL 118 Following TURBT, treatment was allocated (1:1) using computer generated random 119 permuted blocks of size 6, stratified by treating centre and risk group. ICR-CTSU performed 120 the randomisation, and treatment allocation was blinded to participants and investigators. 121 The IDMC reviewed safety and efficacy of the trial blinded to treatment allocation. A 122 Cardiovascular Safety Committee (CVSC) was established to review unblinded cardiovascular 123 safety data to advise in confidence the IDMC. were recruited from 51 centres in the UK (Figure 1 ). Demographics and clinical 178 characteristics were evenly matched across treatment groups (Table 1) . Additional baseline 179 cardiovascular risk factors for both groups are reported in the Supplement Table 1 . 180 A total of 177 (75%) in the celecoxib arm and 189 (80%) patients in the placebo arm took 181 the study drug for ≥12 months, with 120 (51%) and 144 (61%) respectively completing 24 182 months of study treatment (Table 2 ). In December 2013, the trial stopped for futility and 183 given a small increased risk of cardiovascular event in patients on celecoxib, the CVSC, IDMC 184 and TSC recommended halting recruitment of patients still on study treatment (6.8% 185 celecoxib, 7.6% placebo). Follow-up continued until maturity of data at 3 years median 186 follow-up. 187 Compliance with standard of care treatments, by risk group and treatment arm are also 188 shown in 205 The 3-year rate of progression to invasive disease in high risk patients was low in both 206 groups: 10% (6.5%-17%) celecoxib versus 9.7% (6.0%-15%) placebo (log-rank p=0.8) 207 (Supplement Figure 4) . Overall, there were 26 deaths in the celecoxib arm, and 21 in the 208 placebo arm. Deaths were due to bladder cancer (19), other malignancies (14), respiratory 209 causes (6), cardiovascular causes (3) or other (5). At 3 years, the overall survival in the 210 celecoxib arm was 92% (95% CI: 87-95) while in the placebo arm was 94% (90%, 97%) (HR: 211 1.21, [0.68-2.15], stratified log-rank p=0.5) (Supplement Figure 5 ). 212 213 Worst CTC grade adverse events at any time are presented in Table 3 . A total of 145 (32%) 214 patients (30% celecoxib versus 33% placebo) suffered grade 3-4 toxicity (p= 0.6). Only in 70 215 patients (15%) serious adverse events were reported with no differences between groups 216 (celecoxib 16%, placebo 14%, p=0.5). Incidence of CV events reported as serious while on 217 treatment was higher on celecoxib (5.2%) than placebo (1.7%) (absolute difference 3.4% 218 [95% CI: -0.3%-7.2%], p=0.07) (Supplement Table 2 ). NMIBC. Similar findings were reported in a previous RCT on high risk patients [9] . There was 241 no duration dose response as evident in the PP analysis. The results do show a significant 242 benefit in cases with pT1 disease and although not tested in the BOXIT study, studies 243 demonstrate a clear correlation between the expression of COX-2 and tumour stage [14] . 244 Targeting COX-2 inhibition in patients with high risk invasive (pT1) disease although 245 attractive for secondary prevention cannot be recommended because of CV toxicity. Pooled 246 analysis of 6 RCTs report that cardiovascular risk attributed to celecoxib is dependent on 247 dose and baseline cardiovascular risk [15] . The higher cardiovascular event rate in this study 248 compared to others may reflect the fact that bladder cancer patients are often older, 249 smokers and have had previous exposure to environmental hazards compared to the 250 general population despite excluding patients with a history of cardiovascular disease. 251 Whilst selective inhibition of COX-2 was initially thought to be advantageous due to a 252 reduced risk of gastrointestinal ulceration it is apparent that COX-2 plays an important role 253 in the vasculature leading to reduced tendency towards atherothrombosis [16] . However, 254 since many acute coronary events occur in people without a previous history of 255 cardiovascular disease, it is not possible to predict a low risk group for whom prolonged 256 COX-2 therapy would be appropriate. 257 In BOXIT, celecoxib was commenced prior to the start of BCG therapy. COX-2 induces PGE2 258 to alter tumour cytokine microenvironment and dendritic cell antigen presentation [17] . In 259 the preclinical setting, BCG activates dendritic cells resulting in a mixed cytokine response 260 and COX-2 inhibition suppressed PGE2 levels, polarising dendritic cells towards an anti-261 tumour Th1 response [18, 19] . Altering the cytokine response to BCG therapy with COX-2 262 inhibition represents an attractive area for future research given the interest in check-point 263 inhibitors in the NMIBC setting [20] . 264 There is a paucity of HRQOL patient reported outcomes in NMIBC. In one other RCT of 120 265 patients, Gontero and colleagues reported a decline in global health following BCG induction 266 therapy which improved to near baseline levels at 12 months [21] . Further exploration of 267 HRQOL patterns and changes over time in BOXIT is planned. 268 The results from BOXIT may point to an alternative strategy. A study of patients with Lynch 269 syndrome randomised to either aspirin or placebo showed a risk reduction of developing 270 colorectal carcinoma in patients with >2 years of aspirin therapy [22] . Furthermore the 271 benefit of aspirin is greatest in colorectal cancers which overexpress COX-2 (RR: 0.64; 95% CI 272 0.52-0.8) but not in tumours with a low or absent COX-2 expression [23] . It will be important 273 to understand whether non-selective COX-2 agents such as aspirin is an effective 274 chemoprevention option in high COX-2 expressing bladder cancers. Take home message Celecoxib did not reduce the overall risk of recurrence in intermediate or high risk non-muscle invasive bladder cancer. Sub-group analysis report that time to recurrence was significantly longer in pT1 patients treated with celecoxib although cardiovascular events were higher.
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